Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

Milagritos D. Tapia, Samba O. Sow, Kirsten E. Lyke, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Awa Traore, Flanon Coulibaly, Mamoudou Kodio, Uma Onwuchekwa, Marcelo B. Sztein, Rezwanul Wahid, James D. Campbell, Marie Paule Kieny, Vasee Moorthy, Egeruan B. Imoukhuede, Tommy Rampling, Francois Roman, Iris De Ryck, Abbie R. BellamyLen Dally, Olivier Tshiani Mbaya, Aurélie Ploquin, Yan Zhou, Daphne A. Stanley, Robert Bailer, Richard A. Koup, Mario Roederer, Julie Ledgerwood, Adrian V.S. Hill, W. Ripley Ballou, Nancy Sullivan, Barney Graham, Myron M. Levine*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

145 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences